111In antisense oligonucleotide

N/A

Report date: 2025/11/24 17:58:27

NME

Base Information

Drug Name111In antisense oligonucleotide

Drug Alias Name111In-labelled antisense oligonucleotide (p21WAF-1/CIP-1)

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisenseRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Indium > 111In +[5]

Mechanisms of ActionCyclin-dependent kinase inhibitors

TargetsCyclin-dependent kinase

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Toronto - St. George Campus

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity Of Toronto - St. George Campus

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A